Quetiapine-Induced Hypomania and its Association with Quetiapine/Norquetiapine Plasma Concentrations : A Case Series of Bipolar Type 2 Patients by C. Rovera et al.
CASE SERIES
Quetiapine-Induced Hypomania and its Association
with Quetiapine/Norquetiapine Plasma Concentrations: A Case
Series of Bipolar Type 2 Patients
C. Rovera1 • C. M. Esposito1 • V. Ciappolino1 • D. Cattaneo2 • S. Baldelli2 •
E. Clementi3,4 • A. C. Altamura1 • M. Buoli1
 The Author(s) 2017. This article is an open access publication
Abstract International guidelines consider quetiapine at
medium doses (300–400 mg/day) as valid options for the
treatment of bipolar depression for the supposed lower risk
of a switch to hypomania/mania than antidepressants.
Norquetiapine is an active metabolite with antidepressant
action. We describe three cases of induced hypomania in
bipolar type 2 subjects who received quetiapine extended-
release monotherapy (300 mg/day) for a mild/moderate
major depressive episode. Quetiapine and norquetiapine
plasma concentrations were measured after 1 week of
treatment. Hypomania appeared after 7–10 days of queti-
apine extended-release monotherapy and all subjects had a
quetiapine/norquetiapine plasma concentration ratio \1.
We propose a ratio value \1 as a predictor of risk for a
switch to hypomania in bipolar depressed subjects receiv-
ing quetiapine extended-release monotherapy. Future
research should ascertain the validity of this laboratory
parameter to assess the risk of quetiapine-induced hypo-
mania in large samples of bipolar patients.
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Key Points
Quetiapine monotherapy is a therapeutic option for
the treatment of depressive symptoms in bipolar type
2 patients.
Quetiapine has a potential risk of induced hypomania
owing to the antidepressant effect of its metabolite
norquetiapine.
A ratio of quetiapine/norquetiapine plasma
concentrations\1 is thought to be a risk factor for
developing quetiapine-induced hypomania.
Introduction
Bipolar disorder (BD) is a prevalent psychiatric condition
(affecting up to 5–6% of the general population) [1]
associated with high disability and a risk of chronicity if
not promptly treated [2]. Approved in 1997 by the US Food
and Drug Administration for the treatment of acute epi-
sodes of schizophrenia, quetiapine has been shown to be
effective in a large number of neuropsychiatric disorders,
including BD [3, 4]. Currently, both the European
Medicines Agency and the US Food and Drug Adminis-
tration recommend quetiapine for the treatment of major
depressive and manic episodes as well as for the prevention
of recurrences in BD. With regard to acute mood episodes,
the World Federation of Societies of Biological Psychiatry
guidelines consider quetiapine as a compound with high
evidence of efficacy at the dosage of 600–800 mg/day for
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acute mania [5] and at the dosage of 300–600 mg/day for
bipolar depression [6]. In addition, according to the
Canadian Network for Mood and Anxiety Treatments [7],
quetiapine is the only drug recommended as first-line
treatment for major depressive episodes in BD type 2.
Quetiapine appears to be one of the best options in terms
of efficacy in bipolar depression and of risk of switching to
hypomania/mania [8]. Quetiapine-induced hypomania or
mania has been previously described [9, 10]; however,
because the cases of quetiapine-induced hypomania are
extremely rare in comparison with the antidepressant-in-
duced cases [11, 12], quetiapine remains widely prescribed
in the clinical practice for the treatment of bipolar
depression [13].
Norquetiapine, the most important active metabolite of
quetiapine, has been shown to be associated with antide-
pressant, anxiolytic, and neurotrophic effects in humans
[14]. In particular, norquetiapine facilitates dopamine
release in the prefrontal cortex and inhibits dopamine
reuptake [15, 16]. Moreover, norquetiapine potentiates
serotoninergic and noradrenergic transmission through its
high affinity for 5-HT1A, 5-HT2C, and 5-HT7 receptors and
through noradrenaline reuptake inhibition [17, 18]. Previ-
ous studies have showed that the ratio of norquetiap-
ine/quetiapine plasma concentrations was associated with
an improvement of mood symptoms in bipolar patients
[19, 20]. In the first study [19], bipolar patients showed a
curvilinear relationship between the norquetiapine/queti-
apine concentration ratio and the improvement of depres-
sive symptoms after 3 months of treatment with quetiapine.
In the second and more recent study [20], bipolar patients
were found to have a significant correlation between
improvement of depressive symptoms and the norquetiap-
ine/quetiapine ratio, measured after 3 months of quetiapine
treatment. In other studies, however, norquetiapine has
been reported as possibly responsible for a switch to
hypomania in bipolar subjects in treatment with quetiapine
[9, 10], thus the measurement of norquetiapine plasma
concentrations might be useful to evaluate the risk of a
switch to hypomania in depressed bipolar subjects. In this
article, we describe three cases of quetiapine-induced
hypomania in subjects who were monitored for quetiapine
and norquetiapine plasma concentrations.
Case Series
Three bipolar type 2 patients with a moderate major
depressive episode according to the Diagnostic and Sta-
tistical Manual of Mental Disorders, Fifth Revision [21]
had a switch to hypomania during quetiapine monotherapy.
They were outpatients of the Department of Psychiatry,
University of Milan. The patients provided consent to share
their clinical data for research purposes. All patients
underwent laboratory evaluations such as blood cell count,
renal function tests, pancreatic and liver enzymes, and also
safety assessments (neurological examination and electro-
cardiography). All the examination results were normal.
All subjects were treated with 300 mg/day of quetiapine
extended release (ER). After 1 week of treatment, queti-
apine and norquetiapine plasma concentrations were mea-
sured, considering that steady state is usually achieved after
3 days of sequential doses [22]. Young Mania Rating Scale
(YMRS), Hamilton Depression Rating Scale (HAM-D),
Hamilton Anxiety Rating Scale (HAM-A), and Brief Psy-
chiatric Rating Scale (BPRS) were administered after
1 week (T1) and after 1 month of treatment (T2). Hypo-
mania was defined not only according to the Diagnostic
and Statistical Manual of Mental Disorders, Fifth Revision
criteria, but also by an YMRS score C 10 [23]. The
patients did not receive other psychotropic drugs during the
follow-up period. In addition, all the patients had discon-
tinued autonomously the previous pharmacotherapy for at
least 3 months. None of the subjects developed side effects
except for induced hypomania. Changes in rating scale
scores for the three patients are reported in Fig. 1.
The first case was a 28-year-old woman who had the
first diagnosis of BD type 2 in 2007, while experiencing a
hypomanic episode subsequent to a major depressive epi-
sode. In the last years, she experienced two further major
depressive episodes and three hypomanic episodes. She has
a family history of psychiatric disorders: her mother
experienced a major depressive disorder, while one sister
and one brother received a diagnosis of generalized anxiety
disorder. Substance misuse was never reported by the
patient, while she experienced Hashimoto thyroiditis
(currently in remission and treated with hormone replace-
ment therapy) and polycystic ovary syndrome (currently in
remission and treated with a combined hormonal contra-
ceptive). At the time of the first evaluation (T0), she pre-
sented with a mild major depressive episode (YMRS = 8;
HAM-D = 17; HAM-A = 28; BPRS = 38). Pharma-
cotherapy with quetiapine ER 300 mg/day was prescribed
and, after 1 week (T1), quetiapine and norquetiapine
plasma concentrations were 113.9 and 178.1 ng/mL,
respectively (ratio = 0.64). The scores of the clinical rat-
ing scales were the following: T1: YMRS = 11; HAM-
D = 13; HAM-A = 25; BPRS = 36; T2: YMRS = 14;
HAM-D = 8; HAM-A = 23; BPRS = 32. The clinical
rating scale scores show the improvement of depressive
symptoms, but also the early switch to hypomania (after
1 week of treatment).
The second case was a 45-year-old woman who first
visited our outpatient clinic in 2005 because of a hypo-
manic episode followed by a major depressive episode. At
that time, she had already presented with several mood
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episodes, starting from the age of 20 years, when she
received a diagnosis of BD type 2, and she had been hos-
pitalized three times for major depressive episodes. Her
father had experienced a major depressive disorder, while
her mother presented with a generalized anxiety disorder.
No substance abuse was reported by the patient, while she
had a head trauma following a road accident in 1998 at the
age of 26 years, without any long-term consequences (no
specific lesions were documented by a subsequent brain
scan with computerized tomography). At baseline (T0), the
patient presented with a mild major depressive episode
(YMRS = 7; HAM-D = 16; HAM-A = 27; BPRS = 31)
and pharmacotherapy with quetiapine ER 300 mg/day was
prescribed. After 1 week (T1), quetiapine and
norquetiapine plasma concentrations were respectively 5
and 10.1 ng/mL (ratio = 0.59). The rating scale scores
were the following: T1: YMRS = 11, HAM-D = 13,
HAM-A = 25, BPRS = 36; T2: YMRS = 13, HAM-
D = 8, HAM-A = 21, BPRS = 32. The patient presented
with an improvement of depressive symptoms, but also an
early switch to hypomania (after 1 week of treatment).
The third case was a 25-year-old woman who developed
obsessive-compulsive symptoms at the age of 12 years.
She has a family history of psychiatric disorders: her father
and her grandmother were affected by major depressive
disorder, while her brother and an aunt experienced a
generalized anxiety disorder. Neither substance abuse nor
medical comorbidity was reported by the patient. When she
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Fig. 1 Rating scale scores of the three patients during the 1-month follow-up period
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started university at the age of 19 years, she showed a
worsening of obsessive symptoms and received treatment
with citalopram 25 mg/day for 1 year. There was an
improvement of obsessive-compulsive symptoms, but also
a switch to hypomania, followed by a major depressive
episode. In the last 5 years, the patient presented with
several episodes of mood alteration (including three
spontaneous hypomanic episodes, two major depressive
episodes, and one episode of antidepressant-induced
hypomania) and has been followed up at our outpatient
clinic with a diagnosis of BD type 2. The patient received
only citalopram during major depressive episodes (the last
two treatments in combination with a mood stabilizer or
atypical antipsychotic different from quetiapine). At T0,
she experienced a moderate major depressive episode (T0:
YMRS = 7; HAM-D = 21; HAM-A = 27; BPRS = 32)
and pharmacotherapy with quetiapine ER 300 mg/day was
prescribed. The patient showed an amelioration of
depressive symptoms, but also a switch to hypomania (after
10 days). The rating scale scores were the following: T1:
YMRS = 10, HAM-D = 17, HAM-A = 25, BPRS = 30;
T2: YMRS = 15, HAM-D = 7, HAM-A = 18,
BPRS = 25. After 1 week (T1), quetiapine and norqueti-
apine plasma concentrations were found to be respectively,
33.7 and 42.5 ng/mL (ratio = 0.79).
After the hypomanic switch, all three patients received
higher doses of quetiapine, which were titrated up to
800 mg/day to have an anti-manic effect. However, no
cytochrome P450 3A4 inhibitor was introduced in the
treatment of these patients. During the period between T1
and T2, none of the patients satisfied the criteria for a major
depressive episode with mixed features. In the next month
after T2, patients showed an amelioration of hypomanic
symptoms till the remission (YMRS\ 7). No patients
developed substantial depressive symptoms (HAM-D\ 4).
This is not surprising as a recent report showed quetiapine
is a slow but effective anti-manic agent [24].
Discussion
The amelioration of depressive symptoms with quetiapine
at the dosage of 300 mg/day in the three presented cases is
in line with reports in the literature indicating that queti-
apine ER at this dosage has antidepressant efficacy [8].
Despite the well-known metabolic side effects, this drug
appears to also be a valid option for the treatment of major
depressive episodes in bipolar type 2 patients with a sup-
posed lower risk of hypomania with respect to antide-
pressants [25]. The novelty of the reported cases is that
quetiapine is associated with a potential risk of hypomania,
a situation not previously described. We also show that
clinical biological/predictors may be useful to detect
susceptibility to a mood switch in bipolar subjects receiv-
ing quetiapine monotherapy. The association between
quetiapine monotherapy and mood switch is demonstrated
by the fact that the medical and psychiatry comorbidities of
the three bipolar subjects, if present, were in remission and
the patients were not treated with other compounds with
the exception of the first patient who received hormone
replacement therapy. In addition, the patients had no his-
tory of rapid cycling and 7–10 days is too short a period to
consider a spontaneous remission of depressive symptoms
[26]. Rapid cycling was excluded according to the Diag-
nostic and Statistical Manual of Mental Disorders, Fifth
Revision criteria (four or more mood episodes/year) [27].
Finally, the patients had mostly a clinical history charac-
terized by hypomanic episodes that started during euthymic
phases and some months after the remission of depressive
symptoms. Although there can be no absolute certainty, it
is reasonable to exclude that hypomania may be the result
of the natural course of BD. Taking into consideration all
the mentioned aspects, according to the Naranjo Adverse
Drug Reaction Probability Scale, hypomania as an adverse
reaction of the administration of quetiapine ER
(300 mg/day) may be considered as probable in the light of
a score of 6 [28].
Quetiapine and norquetiapine plasma concentrations in
the described bipolar subjects showed a high degree of
variation, most likely owing to the inter-variability in
cytochrome P450 functioning [29], as the patients did not
take drugs with pharmacokinetic interactions with queti-
apine or they were smokers. The patients took the therapy
at 10 p.m. and compliance was checked by counting the
pills in the blister. In addition, caregivers ensured treatment
compliance.
As the efficacy of an antidepressant is mainly the result
of the metabolite norquetiapine and there is a substantial
variability of quetiapine/norquetiapine plasma concentra-
tions after the same dose of quetiapine ER, the ratio of the
plasma concentrations of quetiapine/norquetiapine may be
a useful tool to predict the risk of mood destabilization
[30]. Of note, a ratio\ 1 is proposed as a pharmacological
predictor for a switch to hypomania in bipolar subjects
receiving medium doses of quetiapine. In a previous study
published by our group, bipolar patients who had amelio-
rated the depressive symptoms without developing hypo-
mania showed a quetiapine/norquetiapine ratio [ 1 [20].
The results, however, are not totally comparable to those of
the present case series as the evaluation of drug plasma
concentration was done after 3 months of treatment and the
sample consisted of both bipolar type 1 and 2 patients.
Prospective studies with large samples of bipolar
patients are needed to confirm these preliminary results. In
addition, clinicians should evaluate if a combined therapy
(e.g., with valproate) may prevent the risk of quetiapine-
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induced hypomania and if the prophylactic efficacy over-
comes the increased risk of side effects due to combined
therapies [4].
Conclusions
Even though quetiapine monotherapy (300 mg/day) is an
option for the treatment of depressive symptoms of bipolar
type 2 patients, clinicians should take into account the
potential risk of induced hypomania. Some bipolar type 2
subjects may have a predisposition to a switch to hypomania
when treated with low-medium doses of quetiapine
monotherapy. Future studies need to assess the size of the risk
and identify the risk factors of induced hypomania/mania. A
ratio\ 1 of quetiapine/norquetiapine plasma concentrations
might be a useful predictor of the risk of a mood switch. The
validation of this laboratory parameter should be examined by
future research as well as the evaluation of the efficacy of a
combined therapy (e.g., quetiapine plus valproate) in pre-
venting the risk of a mood switch in bipolar depressed subjects
receiving quetiapine monotherapy.
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